Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $206000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 30.41% year-over-year to $206000.0; the TTM figure through Mar 2026 stood at $206000.0 (down 30.41% YoY), while the FY2025 annual figure was $238000.0, down 17.65% from the prior year.
• Other Accumulated Expenses was $206000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $238000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $566000.0 in Q3 2025 to a low of $131000.0 in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $261411.8 across 5 years, with a median of $238000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses tumbled 66.78% in 2022, then jumped 85.78% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $158000.0 in 2022, then surged by 55.06% to $245000.0 in 2023, then climbed by 17.96% to $289000.0 in 2024, then decreased by 17.65% to $238000.0 in 2025, then declined by 13.45% to $206000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $206000.0 (Q1 2026), $238000.0 (Q4 2025), and $566000.0 (Q3 2025), per Business Quant data.